Voranigo是稀有脑肿瘤的癌症药物,在2025年获得最高创新奖,并在多个国家获得批准。 Voranigo, a cancer drug for rare brain tumors, won top innovation awards in 2025 and is approved in multiple countries.

2025年,Servier的癌症药物Voranigo(Vorasidenib)赢得了多个Prix Galien奖,其中包括在美国、波兰和北欧地区的荣誉,承认罕见疾病治疗的创新。 Servier’s cancer drug Voranigo (vorasidenib) has won multiple Prix Galien Awards in 2025, including honors in the U.S., Poland, and the Nordic region, recognizing innovation in rare disease treatments. 已批准用于手术后12岁及以上的特定IDH突变脑瘤患者,在美国,加拿大,澳大利亚,英国,日本和27个欧盟国家以及冰岛,列支敦士登和挪威可用. Approved for patients 12 and older with specific IDH-mutant brain tumors after surgery, it is available in the U.S., Canada, Australia, the UK, Japan, and 27 EU countries plus Iceland, Liechtenstein, and Norway. 在《新英格兰医学杂志》上公布的临床试验显示,逐步无进展的生存情况有所改善。 Clinical trials published in the New England Journal of Medicine showed improved progression-free survival. 这些奖项突出了该药物在精确肿瘤学和以病人为中心的创新方面的影响。 The awards highlight the drug’s impact in precision oncology and patient-centered innovation.